. Comparison of intrahepatic cholesterol levels between control and 20 mg/kg/injection of P900SL-treated arms. Relative liver cholesterol levels normalized with hepatic protein were expressed as mean ± SD. N.S. indicates no statistical significance (P > 0.05).
. Relation between given dose and serum LDL-C levels of P901SL 6 weeks after treatment started. All are data represented as mean ± SD. *P < 0.05. Table S1 . Serum raw cholesterol levels in atherogenic diet-fed mice after 4 weeks of P900SL treatment. Table S2 . Summary of histopathological findings. Table S3 . Toxicological parameters. Blood samples were collected from mice tail veins after 6 weeks of administration.
Supplementary Materials and Methods.
Intrahepatic cholesterol measurement. Frozen liver tissues were collected in tubes with 1 mL of PBS and zirconia balls (ø 5 mm, Irie) and mechanically homogenized for 2 min at 30 oscillations per second by a TissueLyser II apparatus (Qiagen). Total protein concentrations were determined with a detergent compatible assay kit (Bio-Rad) and the suspension of each sample containing 200 µg of protein was taken and added to PBS to obtain 1 mL of sample suspension.
To 3.5 mL of extraction solvent (CHCl 3 : MeOH = 2 : 1, v/v) was added 900 µL of a sample suspension and the resulting suspension were vigorously mixed and incubated at 4ºC for 24 h. An aqueous layer was carefully removed and added 1 mL of distilled water, followed by vortex mixing and centrifugation. The aqueous layer was removed and the organic layer was evaporated under air blowing. Each residual sample was redissolved with 100 µL of solvent (CHCl 3 : MeOH = 2 : 1, v/v) and transferred to polystylene 96-well assay plate. The solvent was removed by incubating at 65ºC and added 20 µL of i PrOH. Measurement was carried out according to the manufacture's procedure by using Cholesterol E-test WAKO.
